Special Issue "Strategies for the Discovery of Antivirals against Respiratory RNA Viruses"
Deadline for manuscript submissions: closed (20 December 2021) | Viewed by 8216
Interests: influenza virus; SARS-CoV; MERS-CoV; antiviral; innate immune response; viral RNA replication
Emerging and re-emerging respiratory RNA viruses, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and G4 swine influenza virus, have become a great threat to global public health. With the exception of influenza A and B viruses and respiratory syncytial virus (RSV), there are no FDA-approved, virus-specific drugs for the treatment of infections with other human respiratory viruses, such as coronaviruses, rhinoviruses, and parainfluenza viruses. Even though influenza viruses have a relatively diverse range of treatment options due to the long-term development of strategies for direct-acting antivirals, the rapid and sporadic generation of genetic mutations has resulted in the circulation of drug-resistant strains. RSV can be treated with an aerosolized antiviral or prevented by a neutralizing antibody; however, there remain limitations to the antiviral drug in terms of specificity and cost-effectiveness.
There is an urgent need for the development of novel antivirals and the identification of drug targets derived from either viral proteins or host factors, by which therapeutic effects could be induced efficiently and sufficiently. This Special Issue focuses on recent progress in antiviral discovery, investigation of the mode-of-action, target validation, and establishment of drug screening methods. We hope that this Special Issue will allow researchers to share scientific insights to help find a therapeutic way to treat human respiratory virus infection-mediated diseases in the ongoing pandemic situation or in order to be prepared for possible upcoming pandemics.
Dr. Meehyein Kim
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- influenza virus
- respiratory viruses
- target validation